Abstract
Abstract not available.
Highlights
We report the long-term clinical responses for patients with PSO who received open-label treatment with Certolizumab pegol (CZP) dosed at 400 mg every two weeks (Q2W) for up to 128 weeks
Data were pooled from three phase 3 trials in adults with PSO: CIMPASI-1 (NCT02326298), CIMPASI-2 (NCT02326272), and CIMPACT (NCT02346240)
Patients with moderate to severe plaque psoriasis were treated with certolizumab pegol dosed at 400 mg every two weeks for up to 128 weeks
Summary
In phase 3 trials, patients with moderate to severe PSO have demonstrated a durable response to CZP over one year (48 weeks) of double-blinded treatment.4,5 We report the long-term clinical responses for patients with PSO who received open-label treatment with CZP dosed at 400 mg every two weeks (Q2W) for up to 128 weeks. At Week 0, patients were randomized to receive CZP 200 mg Q2W (400 mg loading dose at Weeks 0/2/4), CZP 400 mg Q2W, etanercept (CIMPACT only), or placebo.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.